MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program

被引：0
|
作者：
Brassat, David [1 ]
Hautecoeur, Patrick [2 ]
Durand-Dubief, Francoise [3 ]
Castelnovo, Giovanni [4 ]
Derache, Nathalie [5 ]
Bourre, Bertrand [6 ]
Donze, Cecile [2 ]
Ouallet, Jean-Christophe [7 ]
Collongues, Nicolas [8 ]
Simon, Olivier [9 ]
Brion, Guillaume [9 ]
Sedel, Frederic [9 ]
Vermersch, Patrick [10 ]
Lasser, Robert [9 ]
Morteau, Olivier [9 ]
机构：
[1] Univ Hosp Toulouse, Toulouse, France
[2] Catholic Inst Lille, Groupement Hop, Lomme Les Lille, France
[3] Pierre Wertheimer Hosp, Rhone, France
[4] Caremeau Hosp, Rhone, France
[5] CHU Caen, Caen, France
[6] Rouen Normandy Univ, Rouen, France
[7] Univ Bordeaux, Bordeaux, France
[8] Univ Hosp Strasbourg, Strasbourg, France
[9] MedDay Pharmaceut, Paris, France
[10] Univ Lille, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P046
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [1] MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program
    Brassat, D.
    Hautecoeur, P.
    Durand-Dubief, F.
    Castelnovo, G.
    Derache, N.
    Bourre, B.
    Le Page, E.
    Donze, C.
    Audoin, B.
    Ouallet, J-C.
    Collongues, N.
    Simon, O.
    Brion, G.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 936 - 937
  • [2] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [3] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [4] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [5] Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)
    Morteau, Olivier
    Lasser, Robert
    Sedel, Frederic
    Brion, Guillaume
    Tourbah, Ayman
    Simon, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31
  • [6] High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
    Juntas-Morales, Raul
    Pageot, Nicolas
    Bendarraz, Abdelkarim
    Alphandery, Sebastien
    Sedel, Frederic
    Seigle, Stephanie
    Camu, William
    [J]. ECLINICALMEDICINE, 2020, 19
  • [7] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-Scores
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Defer, Gilles
    Laubage, Pierre
    Ruiz, Marta
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 34 - 34
  • [8] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [9] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clanet, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Lapland, David-Axel
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) : 1719 - 1731
  • [10] Effect of MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive MS: 36-Month Follow-up Data
    Vukusic, Sandra
    de Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Simon, Olivier
    Lasser, Robert
    Tourbah, Ayman
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 32 - 33
12345